nodes	percent_of_prediction	percent_of_DWPC	metapath
Risperidone—ABCB1—esophageal cancer	0.366	1	CbGaD
Risperidone—HTR7—vagus nerve—esophageal cancer	0.00905	0.142	CbGeAlD
Risperidone—HTR2A—vagus nerve—esophageal cancer	0.00565	0.0887	CbGeAlD
Risperidone—H1F0—neck—esophageal cancer	0.00322	0.0505	CbGeAlD
Risperidone—H1F0—bronchus—esophageal cancer	0.00216	0.0339	CbGeAlD
Risperidone—H1F0—smooth muscle tissue—esophageal cancer	0.00211	0.0331	CbGeAlD
Risperidone—HTR7—neck—esophageal cancer	0.00199	0.0312	CbGeAlD
Risperidone—H1F0—trachea—esophageal cancer	0.00194	0.0304	CbGeAlD
Risperidone—H1F0—digestive system—esophageal cancer	0.00167	0.0262	CbGeAlD
Risperidone—HTR2B—smooth muscle tissue—esophageal cancer	0.00152	0.0239	CbGeAlD
Risperidone—H1F0—lung—esophageal cancer	0.00139	0.0218	CbGeAlD
Risperidone—HTR7—epithelium—esophageal cancer	0.00135	0.0212	CbGeAlD
Risperidone—ADRA1A—epithelium—esophageal cancer	0.0013	0.0205	CbGeAlD
Risperidone—HTR7—smooth muscle tissue—esophageal cancer	0.0013	0.0204	CbGeAlD
Risperidone—HTR2A—neck—esophageal cancer	0.00124	0.0194	CbGeAlD
Risperidone—ADRA2C—bronchus—esophageal cancer	0.00122	0.0192	CbGeAlD
Risperidone—HTR2B—digestive system—esophageal cancer	0.0012	0.0188	CbGeAlD
Risperidone—HTR7—trachea—esophageal cancer	0.00119	0.0188	CbGeAlD
Risperidone—ADRA2C—trachea—esophageal cancer	0.0011	0.0172	CbGeAlD
Risperidone—HTR7—digestive system—esophageal cancer	0.00103	0.0161	CbGeAlD
Risperidone—HRH1—epithelium—esophageal cancer	0.00101	0.0158	CbGeAlD
Risperidone—HTR2B—lung—esophageal cancer	0.001	0.0157	CbGeAlD
Risperidone—ADRA2A—bronchus—esophageal cancer	0.000976	0.0153	CbGeAlD
Risperidone—HRH1—smooth muscle tissue—esophageal cancer	0.000972	0.0153	CbGeAlD
Risperidone—H1F0—lymph node—esophageal cancer	0.000952	0.0149	CbGeAlD
Risperidone—HRH1—trachea—esophageal cancer	0.000892	0.014	CbGeAlD
Risperidone—ADRA2A—trachea—esophageal cancer	0.000876	0.0138	CbGeAlD
Risperidone—HTR7—lung—esophageal cancer	0.000859	0.0135	CbGeAlD
Risperidone—HTR2A—epithelium—esophageal cancer	0.000843	0.0132	CbGeAlD
Risperidone—HTR2A—smooth muscle tissue—esophageal cancer	0.000812	0.0127	CbGeAlD
Risperidone—DRD2—lung—esophageal cancer	0.000812	0.0127	CbGeAlD
Risperidone—CYP3A5—digestive system—esophageal cancer	0.000791	0.0124	CbGeAlD
Risperidone—ADRA2C—lung—esophageal cancer	0.000789	0.0124	CbGeAlD
Risperidone—HRH1—digestive system—esophageal cancer	0.000768	0.0121	CbGeAlD
Risperidone—HTR2A—trachea—esophageal cancer	0.000745	0.0117	CbGeAlD
Risperidone—HTR2B—lymph node—esophageal cancer	0.000686	0.0108	CbGeAlD
Risperidone—CYP3A5—lung—esophageal cancer	0.00066	0.0104	CbGeAlD
Risperidone—HTR2A—digestive system—esophageal cancer	0.000641	0.0101	CbGeAlD
Risperidone—HRH1—lung—esophageal cancer	0.000641	0.0101	CbGeAlD
Risperidone—ADRA2A—lung—esophageal cancer	0.00063	0.00989	CbGeAlD
Risperidone—CYP3A4—digestive system—esophageal cancer	0.000594	0.00932	CbGeAlD
Risperidone—CYP2D6—digestive system—esophageal cancer	0.000584	0.00917	CbGeAlD
Risperidone—ABCB1—epithelium—esophageal cancer	0.000552	0.00867	CbGeAlD
Risperidone—KCNH2—lymph node—esophageal cancer	0.000547	0.00859	CbGeAlD
Risperidone—ADRA2C—lymph node—esophageal cancer	0.00054	0.00847	CbGeAlD
Risperidone—HTR2A—lung—esophageal cancer	0.000535	0.00841	CbGeAlD
Risperidone—Alopecia—Cisplatin—esophageal cancer	0.00049	0.00138	CcSEcCtD
Risperidone—Abdominal discomfort—Capecitabine—esophageal cancer	0.000489	0.00138	CcSEcCtD
Risperidone—Hepatic failure—Methotrexate—esophageal cancer	0.000489	0.00138	CcSEcCtD
Risperidone—ABCB1—trachea—esophageal cancer	0.000488	0.00767	CbGeAlD
Risperidone—Malnutrition—Cisplatin—esophageal cancer	0.000482	0.00136	CcSEcCtD
Risperidone—Erythema—Cisplatin—esophageal cancer	0.000482	0.00136	CcSEcCtD
Risperidone—Dysuria—Capecitabine—esophageal cancer	0.000477	0.00135	CcSEcCtD
Risperidone—Neutropenia—Capecitabine—esophageal cancer	0.000477	0.00135	CcSEcCtD
Risperidone—Renal failure acute—Methotrexate—esophageal cancer	0.000476	0.00134	CcSEcCtD
Risperidone—Flatulence—Cisplatin—esophageal cancer	0.000475	0.00134	CcSEcCtD
Risperidone—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000474	0.00134	CcSEcCtD
Risperidone—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000466	0.00131	CcSEcCtD
Risperidone—Weight increased—Capecitabine—esophageal cancer	0.000464	0.00131	CcSEcCtD
Risperidone—Muscle spasms—Cisplatin—esophageal cancer	0.000464	0.00131	CcSEcCtD
Risperidone—Weight decreased—Capecitabine—esophageal cancer	0.000462	0.0013	CcSEcCtD
Risperidone—Hyperglycaemia—Capecitabine—esophageal cancer	0.00046	0.0013	CcSEcCtD
Risperidone—Pneumonia—Capecitabine—esophageal cancer	0.000458	0.00129	CcSEcCtD
Risperidone—Infestation NOS—Capecitabine—esophageal cancer	0.000455	0.00128	CcSEcCtD
Risperidone—Infestation—Capecitabine—esophageal cancer	0.000455	0.00128	CcSEcCtD
Risperidone—Vision blurred—Cisplatin—esophageal cancer	0.000455	0.00128	CcSEcCtD
Risperidone—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000454	0.00128	CcSEcCtD
Risperidone—Depression—Capecitabine—esophageal cancer	0.000454	0.00128	CcSEcCtD
Risperidone—Tremor—Cisplatin—esophageal cancer	0.000452	0.00127	CcSEcCtD
Risperidone—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000451	0.00127	CcSEcCtD
Risperidone—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000448	0.00126	CcSEcCtD
Risperidone—Lethargy—Methotrexate—esophageal cancer	0.000448	0.00126	CcSEcCtD
Risperidone—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000448	0.00126	CcSEcCtD
Risperidone—Ill-defined disorder—Cisplatin—esophageal cancer	0.000448	0.00126	CcSEcCtD
Risperidone—Renal failure—Capecitabine—esophageal cancer	0.000447	0.00126	CcSEcCtD
Risperidone—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000446	0.00126	CcSEcCtD
Risperidone—Myocardial infarction—Capecitabine—esophageal cancer	0.000446	0.00126	CcSEcCtD
Risperidone—Anaemia—Cisplatin—esophageal cancer	0.000446	0.00126	CcSEcCtD
Risperidone—Stomatitis—Capecitabine—esophageal cancer	0.000443	0.00125	CcSEcCtD
Risperidone—Jaundice—Capecitabine—esophageal cancer	0.000443	0.00125	CcSEcCtD
Risperidone—Conjunctivitis—Capecitabine—esophageal cancer	0.000442	0.00125	CcSEcCtD
Risperidone—Urinary tract infection—Capecitabine—esophageal cancer	0.000442	0.00125	CcSEcCtD
Risperidone—Osteoarthritis—Methotrexate—esophageal cancer	0.00044	0.00124	CcSEcCtD
Risperidone—HRH1—lymph node—esophageal cancer	0.000438	0.00688	CbGeAlD
Risperidone—Malaise—Cisplatin—esophageal cancer	0.000435	0.00123	CcSEcCtD
Risperidone—Haematuria—Capecitabine—esophageal cancer	0.000434	0.00122	CcSEcCtD
Risperidone—Leukopenia—Cisplatin—esophageal cancer	0.000432	0.00122	CcSEcCtD
Risperidone—ADRA2A—lymph node—esophageal cancer	0.000431	0.00676	CbGeAlD
Risperidone—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00043	0.00121	CcSEcCtD
Risperidone—Epistaxis—Capecitabine—esophageal cancer	0.000429	0.00121	CcSEcCtD
Risperidone—Agranulocytosis—Capecitabine—esophageal cancer	0.000425	0.0012	CcSEcCtD
Risperidone—ABCB1—digestive system—esophageal cancer	0.00042	0.0066	CbGeAlD
Risperidone—Convulsion—Cisplatin—esophageal cancer	0.000418	0.00118	CcSEcCtD
Risperidone—Mood swings—Methotrexate—esophageal cancer	0.000416	0.00117	CcSEcCtD
Risperidone—Bradycardia—Capecitabine—esophageal cancer	0.000416	0.00117	CcSEcCtD
Risperidone—Ataxia—Methotrexate—esophageal cancer	0.000413	0.00117	CcSEcCtD
Risperidone—Myalgia—Cisplatin—esophageal cancer	0.000411	0.00116	CcSEcCtD
Risperidone—Haemoglobin—Capecitabine—esophageal cancer	0.00041	0.00116	CcSEcCtD
Risperidone—Rhinitis—Capecitabine—esophageal cancer	0.000409	0.00115	CcSEcCtD
Risperidone—Anxiety—Cisplatin—esophageal cancer	0.000409	0.00115	CcSEcCtD
Risperidone—Hepatitis—Capecitabine—esophageal cancer	0.000408	0.00115	CcSEcCtD
Risperidone—Haemorrhage—Capecitabine—esophageal cancer	0.000408	0.00115	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000408	0.00115	CcSEcCtD
Risperidone—Hypoaesthesia—Capecitabine—esophageal cancer	0.000406	0.00115	CcSEcCtD
Risperidone—Discomfort—Cisplatin—esophageal cancer	0.000406	0.00114	CcSEcCtD
Risperidone—Pharyngitis—Capecitabine—esophageal cancer	0.000405	0.00114	CcSEcCtD
Risperidone—Urinary tract disorder—Capecitabine—esophageal cancer	0.000403	0.00114	CcSEcCtD
Risperidone—Oedema peripheral—Capecitabine—esophageal cancer	0.000402	0.00113	CcSEcCtD
Risperidone—Connective tissue disorder—Capecitabine—esophageal cancer	0.000401	0.00113	CcSEcCtD
Risperidone—Urethral disorder—Capecitabine—esophageal cancer	0.0004	0.00113	CcSEcCtD
Risperidone—Breast disorder—Methotrexate—esophageal cancer	0.000397	0.00112	CcSEcCtD
Risperidone—Oedema—Cisplatin—esophageal cancer	0.000394	0.00111	CcSEcCtD
Risperidone—Anaphylactic shock—Cisplatin—esophageal cancer	0.000394	0.00111	CcSEcCtD
Risperidone—Visual impairment—Capecitabine—esophageal cancer	0.000394	0.00111	CcSEcCtD
Risperidone—Infection—Cisplatin—esophageal cancer	0.000391	0.0011	CcSEcCtD
Risperidone—Erythema multiforme—Capecitabine—esophageal cancer	0.000386	0.00109	CcSEcCtD
Risperidone—Nervous system disorder—Cisplatin—esophageal cancer	0.000386	0.00109	CcSEcCtD
Risperidone—Thrombocytopenia—Cisplatin—esophageal cancer	0.000385	0.00109	CcSEcCtD
Risperidone—Tachycardia—Cisplatin—esophageal cancer	0.000384	0.00108	CcSEcCtD
Risperidone—Skin disorder—Cisplatin—esophageal cancer	0.000382	0.00108	CcSEcCtD
Risperidone—Eye disorder—Capecitabine—esophageal cancer	0.000382	0.00108	CcSEcCtD
Risperidone—Tinnitus—Capecitabine—esophageal cancer	0.000381	0.00107	CcSEcCtD
Risperidone—Hyperhidrosis—Cisplatin—esophageal cancer	0.000381	0.00107	CcSEcCtD
Risperidone—Asthma—Methotrexate—esophageal cancer	0.00038	0.00107	CcSEcCtD
Risperidone—Cardiac disorder—Capecitabine—esophageal cancer	0.000379	0.00107	CcSEcCtD
Risperidone—Flushing—Capecitabine—esophageal cancer	0.000379	0.00107	CcSEcCtD
Risperidone—Anorexia—Cisplatin—esophageal cancer	0.000375	0.00106	CcSEcCtD
Risperidone—Pancreatitis—Methotrexate—esophageal cancer	0.000372	0.00105	CcSEcCtD
Risperidone—Angiopathy—Capecitabine—esophageal cancer	0.000371	0.00105	CcSEcCtD
Risperidone—Immune system disorder—Capecitabine—esophageal cancer	0.000369	0.00104	CcSEcCtD
Risperidone—Mediastinal disorder—Capecitabine—esophageal cancer	0.000368	0.00104	CcSEcCtD
Risperidone—Hypotension—Cisplatin—esophageal cancer	0.000368	0.00104	CcSEcCtD
Risperidone—Chills—Capecitabine—esophageal cancer	0.000366	0.00103	CcSEcCtD
Risperidone—Arrhythmia—Capecitabine—esophageal cancer	0.000365	0.00103	CcSEcCtD
Risperidone—Abdominal discomfort—Methotrexate—esophageal cancer	0.000364	0.00103	CcSEcCtD
Risperidone—Alopecia—Capecitabine—esophageal cancer	0.000361	0.00102	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000359	0.00101	CcSEcCtD
Risperidone—Mental disorder—Capecitabine—esophageal cancer	0.000358	0.00101	CcSEcCtD
Risperidone—Erythema—Capecitabine—esophageal cancer	0.000356	0.001	CcSEcCtD
Risperidone—Malnutrition—Capecitabine—esophageal cancer	0.000356	0.001	CcSEcCtD
Risperidone—Neutropenia—Methotrexate—esophageal cancer	0.000355	0.001	CcSEcCtD
Risperidone—Dysuria—Methotrexate—esophageal cancer	0.000355	0.001	CcSEcCtD
Risperidone—Paraesthesia—Cisplatin—esophageal cancer	0.000353	0.000997	CcSEcCtD
Risperidone—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000353	0.000996	CcSEcCtD
Risperidone—Dyspnoea—Cisplatin—esophageal cancer	0.000351	0.00099	CcSEcCtD
Risperidone—ABCB1—lung—esophageal cancer	0.000351	0.00551	CbGeAlD
Risperidone—Flatulence—Capecitabine—esophageal cancer	0.00035	0.000988	CcSEcCtD
Risperidone—Erectile dysfunction—Methotrexate—esophageal cancer	0.00035	0.000987	CcSEcCtD
Risperidone—Dysgeusia—Capecitabine—esophageal cancer	0.000348	0.000982	CcSEcCtD
Risperidone—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000347	0.000978	CcSEcCtD
Risperidone—Back pain—Capecitabine—esophageal cancer	0.000344	0.00097	CcSEcCtD
Risperidone—Decreased appetite—Cisplatin—esophageal cancer	0.000342	0.000965	CcSEcCtD
Risperidone—Muscle spasms—Capecitabine—esophageal cancer	0.000342	0.000964	CcSEcCtD
Risperidone—Pneumonia—Methotrexate—esophageal cancer	0.000341	0.000961	CcSEcCtD
Risperidone—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00034	0.000958	CcSEcCtD
Risperidone—Drowsiness—Methotrexate—esophageal cancer	0.000339	0.000955	CcSEcCtD
Risperidone—Infestation—Methotrexate—esophageal cancer	0.000339	0.000955	CcSEcCtD
Risperidone—Infestation NOS—Methotrexate—esophageal cancer	0.000339	0.000955	CcSEcCtD
Risperidone—Depression—Methotrexate—esophageal cancer	0.000338	0.000952	CcSEcCtD
Risperidone—Pain—Cisplatin—esophageal cancer	0.000337	0.000949	CcSEcCtD
Risperidone—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000336	0.000947	CcSEcCtD
Risperidone—Vision blurred—Capecitabine—esophageal cancer	0.000335	0.000945	CcSEcCtD
Risperidone—Tremor—Capecitabine—esophageal cancer	0.000333	0.000939	CcSEcCtD
Risperidone—Renal failure—Methotrexate—esophageal cancer	0.000333	0.000939	CcSEcCtD
Risperidone—Stomatitis—Methotrexate—esophageal cancer	0.00033	0.000931	CcSEcCtD
Risperidone—Ill-defined disorder—Capecitabine—esophageal cancer	0.00033	0.00093	CcSEcCtD
Risperidone—Conjunctivitis—Methotrexate—esophageal cancer	0.000329	0.000928	CcSEcCtD
Risperidone—Anaemia—Capecitabine—esophageal cancer	0.000329	0.000927	CcSEcCtD
Risperidone—Sweating—Methotrexate—esophageal cancer	0.000325	0.000916	CcSEcCtD
Risperidone—Feeling abnormal—Cisplatin—esophageal cancer	0.000324	0.000915	CcSEcCtD
Risperidone—Haematuria—Methotrexate—esophageal cancer	0.000323	0.000911	CcSEcCtD
Risperidone—Malaise—Capecitabine—esophageal cancer	0.000321	0.000904	CcSEcCtD
Risperidone—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00032	0.000903	CcSEcCtD
Risperidone—Epistaxis—Methotrexate—esophageal cancer	0.000319	0.000901	CcSEcCtD
Risperidone—Vertigo—Capecitabine—esophageal cancer	0.000319	0.000901	CcSEcCtD
Risperidone—Syncope—Capecitabine—esophageal cancer	0.000319	0.000899	CcSEcCtD
Risperidone—Leukopenia—Capecitabine—esophageal cancer	0.000318	0.000898	CcSEcCtD
Risperidone—Agranulocytosis—Methotrexate—esophageal cancer	0.000316	0.000891	CcSEcCtD
Risperidone—Palpitations—Capecitabine—esophageal cancer	0.000314	0.000886	CcSEcCtD
Risperidone—Loss of consciousness—Capecitabine—esophageal cancer	0.000312	0.000881	CcSEcCtD
Risperidone—Body temperature increased—Cisplatin—esophageal cancer	0.000311	0.000878	CcSEcCtD
Risperidone—Cough—Capecitabine—esophageal cancer	0.00031	0.000875	CcSEcCtD
Risperidone—Hypertension—Capecitabine—esophageal cancer	0.000307	0.000866	CcSEcCtD
Risperidone—Haemoglobin—Methotrexate—esophageal cancer	0.000306	0.000862	CcSEcCtD
Risperidone—Haemorrhage—Methotrexate—esophageal cancer	0.000304	0.000857	CcSEcCtD
Risperidone—Hepatitis—Methotrexate—esophageal cancer	0.000304	0.000857	CcSEcCtD
Risperidone—Chest pain—Capecitabine—esophageal cancer	0.000303	0.000854	CcSEcCtD
Risperidone—Myalgia—Capecitabine—esophageal cancer	0.000303	0.000854	CcSEcCtD
Risperidone—Arthralgia—Capecitabine—esophageal cancer	0.000303	0.000854	CcSEcCtD
Risperidone—Pharyngitis—Methotrexate—esophageal cancer	0.000302	0.000851	CcSEcCtD
Risperidone—Anxiety—Capecitabine—esophageal cancer	0.000302	0.000851	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000301	0.000848	CcSEcCtD
Risperidone—Urinary tract disorder—Methotrexate—esophageal cancer	0.0003	0.000847	CcSEcCtD
Risperidone—Discomfort—Capecitabine—esophageal cancer	0.000299	0.000843	CcSEcCtD
Risperidone—Urethral disorder—Methotrexate—esophageal cancer	0.000298	0.000841	CcSEcCtD
Risperidone—Dry mouth—Capecitabine—esophageal cancer	0.000296	0.000835	CcSEcCtD
Risperidone—Visual impairment—Methotrexate—esophageal cancer	0.000293	0.000826	CcSEcCtD
Risperidone—Confusional state—Capecitabine—esophageal cancer	0.000293	0.000825	CcSEcCtD
Risperidone—Oedema—Capecitabine—esophageal cancer	0.00029	0.000818	CcSEcCtD
Risperidone—Hypersensitivity—Cisplatin—esophageal cancer	0.00029	0.000818	CcSEcCtD
Risperidone—Infection—Capecitabine—esophageal cancer	0.000288	0.000813	CcSEcCtD
Risperidone—Erythema multiforme—Methotrexate—esophageal cancer	0.000287	0.000811	CcSEcCtD
Risperidone—Shock—Capecitabine—esophageal cancer	0.000285	0.000805	CcSEcCtD
Risperidone—Nervous system disorder—Capecitabine—esophageal cancer	0.000285	0.000803	CcSEcCtD
Risperidone—Eye disorder—Methotrexate—esophageal cancer	0.000284	0.000801	CcSEcCtD
Risperidone—Thrombocytopenia—Capecitabine—esophageal cancer	0.000284	0.000801	CcSEcCtD
Risperidone—Tinnitus—Methotrexate—esophageal cancer	0.000283	0.000799	CcSEcCtD
Risperidone—Tachycardia—Capecitabine—esophageal cancer	0.000283	0.000799	CcSEcCtD
Risperidone—Asthenia—Cisplatin—esophageal cancer	0.000282	0.000797	CcSEcCtD
Risperidone—Cardiac disorder—Methotrexate—esophageal cancer	0.000282	0.000796	CcSEcCtD
Risperidone—Skin disorder—Capecitabine—esophageal cancer	0.000282	0.000795	CcSEcCtD
Risperidone—Hyperhidrosis—Capecitabine—esophageal cancer	0.000281	0.000791	CcSEcCtD
Risperidone—Anorexia—Capecitabine—esophageal cancer	0.000277	0.00078	CcSEcCtD
Risperidone—Angiopathy—Methotrexate—esophageal cancer	0.000276	0.000778	CcSEcCtD
Risperidone—Immune system disorder—Methotrexate—esophageal cancer	0.000275	0.000775	CcSEcCtD
Risperidone—Mediastinal disorder—Methotrexate—esophageal cancer	0.000274	0.000773	CcSEcCtD
Risperidone—Chills—Methotrexate—esophageal cancer	0.000273	0.000769	CcSEcCtD
Risperidone—Hypotension—Capecitabine—esophageal cancer	0.000271	0.000765	CcSEcCtD
Risperidone—Diarrhoea—Cisplatin—esophageal cancer	0.000269	0.00076	CcSEcCtD
Risperidone—Alopecia—Methotrexate—esophageal cancer	0.000269	0.000758	CcSEcCtD
Risperidone—Mental disorder—Methotrexate—esophageal cancer	0.000266	0.000751	CcSEcCtD
Risperidone—Malnutrition—Methotrexate—esophageal cancer	0.000265	0.000746	CcSEcCtD
Risperidone—Erythema—Methotrexate—esophageal cancer	0.000265	0.000746	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000264	0.000746	CcSEcCtD
Risperidone—Insomnia—Capecitabine—esophageal cancer	0.000262	0.00074	CcSEcCtD
Risperidone—Paraesthesia—Capecitabine—esophageal cancer	0.000261	0.000735	CcSEcCtD
Risperidone—Dysgeusia—Methotrexate—esophageal cancer	0.000259	0.000731	CcSEcCtD
Risperidone—Dyspnoea—Capecitabine—esophageal cancer	0.000259	0.00073	CcSEcCtD
Risperidone—Back pain—Methotrexate—esophageal cancer	0.000256	0.000722	CcSEcCtD
Risperidone—Dyspepsia—Capecitabine—esophageal cancer	0.000255	0.00072	CcSEcCtD
Risperidone—Decreased appetite—Capecitabine—esophageal cancer	0.000252	0.000711	CcSEcCtD
Risperidone—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000251	0.000707	CcSEcCtD
Risperidone—Vomiting—Cisplatin—esophageal cancer	0.00025	0.000706	CcSEcCtD
Risperidone—Fatigue—Capecitabine—esophageal cancer	0.00025	0.000706	CcSEcCtD
Risperidone—Vision blurred—Methotrexate—esophageal cancer	0.000249	0.000703	CcSEcCtD
Risperidone—Rash—Cisplatin—esophageal cancer	0.000248	0.0007	CcSEcCtD
Risperidone—Pain—Capecitabine—esophageal cancer	0.000248	0.0007	CcSEcCtD
Risperidone—Constipation—Capecitabine—esophageal cancer	0.000248	0.0007	CcSEcCtD
Risperidone—Dermatitis—Cisplatin—esophageal cancer	0.000248	0.000699	CcSEcCtD
Risperidone—Ill-defined disorder—Methotrexate—esophageal cancer	0.000246	0.000693	CcSEcCtD
Risperidone—Anaemia—Methotrexate—esophageal cancer	0.000245	0.00069	CcSEcCtD
Risperidone—ABCB1—lymph node—esophageal cancer	0.00024	0.00377	CbGeAlD
Risperidone—Feeling abnormal—Capecitabine—esophageal cancer	0.000239	0.000674	CcSEcCtD
Risperidone—Malaise—Methotrexate—esophageal cancer	0.000239	0.000673	CcSEcCtD
Risperidone—Vertigo—Methotrexate—esophageal cancer	0.000238	0.000671	CcSEcCtD
Risperidone—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000237	0.000669	CcSEcCtD
Risperidone—Leukopenia—Methotrexate—esophageal cancer	0.000237	0.000668	CcSEcCtD
Risperidone—Nausea—Cisplatin—esophageal cancer	0.000234	0.000659	CcSEcCtD
Risperidone—Cough—Methotrexate—esophageal cancer	0.000231	0.000651	CcSEcCtD
Risperidone—Urticaria—Capecitabine—esophageal cancer	0.000231	0.00065	CcSEcCtD
Risperidone—Abdominal pain—Capecitabine—esophageal cancer	0.000229	0.000647	CcSEcCtD
Risperidone—Body temperature increased—Capecitabine—esophageal cancer	0.000229	0.000647	CcSEcCtD
Risperidone—Convulsion—Methotrexate—esophageal cancer	0.000229	0.000647	CcSEcCtD
Risperidone—Arthralgia—Methotrexate—esophageal cancer	0.000225	0.000635	CcSEcCtD
Risperidone—Chest pain—Methotrexate—esophageal cancer	0.000225	0.000635	CcSEcCtD
Risperidone—Myalgia—Methotrexate—esophageal cancer	0.000225	0.000635	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000224	0.000631	CcSEcCtD
Risperidone—Discomfort—Methotrexate—esophageal cancer	0.000223	0.000628	CcSEcCtD
Risperidone—Confusional state—Methotrexate—esophageal cancer	0.000218	0.000614	CcSEcCtD
Risperidone—Anaphylactic shock—Methotrexate—esophageal cancer	0.000216	0.000609	CcSEcCtD
Risperidone—Infection—Methotrexate—esophageal cancer	0.000215	0.000605	CcSEcCtD
Risperidone—Hypersensitivity—Capecitabine—esophageal cancer	0.000214	0.000603	CcSEcCtD
Risperidone—Nervous system disorder—Methotrexate—esophageal cancer	0.000212	0.000597	CcSEcCtD
Risperidone—Thrombocytopenia—Methotrexate—esophageal cancer	0.000211	0.000596	CcSEcCtD
Risperidone—Skin disorder—Methotrexate—esophageal cancer	0.00021	0.000592	CcSEcCtD
Risperidone—Hyperhidrosis—Methotrexate—esophageal cancer	0.000209	0.000589	CcSEcCtD
Risperidone—Asthenia—Capecitabine—esophageal cancer	0.000208	0.000587	CcSEcCtD
Risperidone—Anorexia—Methotrexate—esophageal cancer	0.000206	0.000581	CcSEcCtD
Risperidone—Pruritus—Capecitabine—esophageal cancer	0.000205	0.000579	CcSEcCtD
Risperidone—Hypotension—Methotrexate—esophageal cancer	0.000202	0.000569	CcSEcCtD
Risperidone—Diarrhoea—Capecitabine—esophageal cancer	0.000199	0.00056	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000197	0.000555	CcSEcCtD
Risperidone—Insomnia—Methotrexate—esophageal cancer	0.000195	0.000551	CcSEcCtD
Risperidone—Paraesthesia—Methotrexate—esophageal cancer	0.000194	0.000547	CcSEcCtD
Risperidone—Dyspnoea—Methotrexate—esophageal cancer	0.000193	0.000543	CcSEcCtD
Risperidone—Somnolence—Methotrexate—esophageal cancer	0.000192	0.000542	CcSEcCtD
Risperidone—Dizziness—Capecitabine—esophageal cancer	0.000192	0.000541	CcSEcCtD
Risperidone—Dyspepsia—Methotrexate—esophageal cancer	0.00019	0.000536	CcSEcCtD
Risperidone—Decreased appetite—Methotrexate—esophageal cancer	0.000188	0.00053	CcSEcCtD
Risperidone—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000186	0.000526	CcSEcCtD
Risperidone—Fatigue—Methotrexate—esophageal cancer	0.000186	0.000525	CcSEcCtD
Risperidone—Pain—Methotrexate—esophageal cancer	0.000185	0.000521	CcSEcCtD
Risperidone—Vomiting—Capecitabine—esophageal cancer	0.000184	0.00052	CcSEcCtD
Risperidone—Rash—Capecitabine—esophageal cancer	0.000183	0.000516	CcSEcCtD
Risperidone—Dermatitis—Capecitabine—esophageal cancer	0.000183	0.000516	CcSEcCtD
Risperidone—Headache—Capecitabine—esophageal cancer	0.000182	0.000513	CcSEcCtD
Risperidone—Feeling abnormal—Methotrexate—esophageal cancer	0.000178	0.000502	CcSEcCtD
Risperidone—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000177	0.000498	CcSEcCtD
Risperidone—Nausea—Capecitabine—esophageal cancer	0.000172	0.000486	CcSEcCtD
Risperidone—Urticaria—Methotrexate—esophageal cancer	0.000172	0.000484	CcSEcCtD
Risperidone—Abdominal pain—Methotrexate—esophageal cancer	0.000171	0.000482	CcSEcCtD
Risperidone—Body temperature increased—Methotrexate—esophageal cancer	0.000171	0.000482	CcSEcCtD
Risperidone—Hypersensitivity—Methotrexate—esophageal cancer	0.000159	0.000449	CcSEcCtD
Risperidone—Asthenia—Methotrexate—esophageal cancer	0.000155	0.000437	CcSEcCtD
Risperidone—Pruritus—Methotrexate—esophageal cancer	0.000153	0.000431	CcSEcCtD
Risperidone—Diarrhoea—Methotrexate—esophageal cancer	0.000148	0.000417	CcSEcCtD
Risperidone—Dizziness—Methotrexate—esophageal cancer	0.000143	0.000403	CcSEcCtD
Risperidone—Vomiting—Methotrexate—esophageal cancer	0.000137	0.000387	CcSEcCtD
Risperidone—Rash—Methotrexate—esophageal cancer	0.000136	0.000384	CcSEcCtD
Risperidone—Dermatitis—Methotrexate—esophageal cancer	0.000136	0.000384	CcSEcCtD
Risperidone—Headache—Methotrexate—esophageal cancer	0.000135	0.000382	CcSEcCtD
Risperidone—Nausea—Methotrexate—esophageal cancer	0.000128	0.000362	CcSEcCtD
Risperidone—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	1.47e-05	6.82e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—HIF1A—esophageal cancer	1.47e-05	6.8e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling by GPCR—PIK3CA—esophageal cancer	1.46e-05	6.78e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—NOTCH1—esophageal cancer	1.46e-05	6.77e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—CYP19A1—esophageal cancer	1.45e-05	6.74e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—NOS3—esophageal cancer	1.45e-05	6.71e-05	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—NOS3—esophageal cancer	1.44e-05	6.68e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—CREBBP—esophageal cancer	1.44e-05	6.68e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—HIF1A—esophageal cancer	1.44e-05	6.67e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—ERBB2—esophageal cancer	1.43e-05	6.66e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—KDR—esophageal cancer	1.43e-05	6.63e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—NOS3—esophageal cancer	1.43e-05	6.62e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—GNG7—esophageal cancer	1.42e-05	6.6e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling by GPCR—EGFR—esophageal cancer	1.41e-05	6.56e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—HMOX1—esophageal cancer	1.41e-05	6.53e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—KDR—esophageal cancer	1.41e-05	6.52e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—KDR—esophageal cancer	1.4e-05	6.5e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	1.39e-05	6.44e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—CCND1—esophageal cancer	1.39e-05	6.43e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	1.38e-05	6.41e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—CCND1—esophageal cancer	1.38e-05	6.39e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling by GPCR—PIK3CA—esophageal cancer	1.38e-05	6.39e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—KDR—esophageal cancer	1.38e-05	6.38e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	1.37e-05	6.33e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling by GPCR—PIK3CA—esophageal cancer	1.36e-05	6.31e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	1.36e-05	6.3e-05	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—PTGS2—esophageal cancer	1.36e-05	6.29e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—ERBB2—esophageal cancer	1.35e-05	6.28e-05	CbGpPWpGaD
Risperidone—ADRA2B—GPCR downstream signaling—PIK3CA—esophageal cancer	1.35e-05	6.27e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—CCND1—esophageal cancer	1.35e-05	6.26e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	1.35e-05	6.24e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—CREBBP—esophageal cancer	1.34e-05	6.24e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—CDKN1A—esophageal cancer	1.34e-05	6.22e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	1.34e-05	6.2e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—ERBB2—esophageal cancer	1.33e-05	6.19e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.33e-05	6.19e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—CDKN1A—esophageal cancer	1.33e-05	6.18e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—CCND1—esophageal cancer	1.33e-05	6.16e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.33e-05	6.15e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	1.32e-05	6.14e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—CREBBP—esophageal cancer	1.32e-05	6.14e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—EGFR—esophageal cancer	1.32e-05	6.13e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—NOTCH1—esophageal cancer	1.32e-05	6.13e-05	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—PTGS2—esophageal cancer	1.32e-05	6.11e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—CREBBP—esophageal cancer	1.31e-05	6.06e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—CDKN1A—esophageal cancer	1.31e-05	6.06e-05	CbGpPWpGaD
Risperidone—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.3e-05	6.05e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—EGFR—esophageal cancer	1.3e-05	6.03e-05	CbGpPWpGaD
Risperidone—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	1.3e-05	6.02e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	1.3e-05	6.01e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—NOS3—esophageal cancer	1.29e-05	5.98e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—CDKN1A—esophageal cancer	1.28e-05	5.96e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—KDR—esophageal cancer	1.28e-05	5.93e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—EP300—esophageal cancer	1.28e-05	5.92e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.27e-05	5.91e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.27e-05	5.89e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—EP300—esophageal cancer	1.27e-05	5.88e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—CCND1—esophageal cancer	1.27e-05	5.88e-05	CbGpPWpGaD
Risperidone—ADRA2C—GPCR downstream signaling—PIK3CA—esophageal cancer	1.26e-05	5.86e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.25e-05	5.82e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—NOS3—esophageal cancer	1.24e-05	5.77e-05	CbGpPWpGaD
Risperidone—ADRA1B—GPCR downstream signaling—PIK3CA—esophageal cancer	1.24e-05	5.76e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—EP300—esophageal cancer	1.24e-05	5.76e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—NOS3—esophageal cancer	1.24e-05	5.74e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling by GPCR—PIK3CA—esophageal cancer	1.23e-05	5.69e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—CDKN1A—esophageal cancer	1.23e-05	5.69e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—EP300—esophageal cancer	1.22e-05	5.67e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CREBBP—esophageal cancer	1.22e-05	5.66e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—ERBB2—esophageal cancer	1.21e-05	5.59e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	1.2e-05	5.59e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—NOS3—esophageal cancer	1.2e-05	5.58e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	1.2e-05	5.57e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—EGFR—esophageal cancer	1.2e-05	5.56e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CREBBP—esophageal cancer	1.2e-05	5.56e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—CREBBP—esophageal cancer	1.2e-05	5.55e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—CCND1—esophageal cancer	1.2e-05	5.55e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—ENO1—esophageal cancer	1.19e-05	5.51e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.19e-05	5.51e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	1.18e-05	5.5e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—NOS3—esophageal cancer	1.18e-05	5.5e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—CCND1—esophageal cancer	1.18e-05	5.47e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	1.18e-05	5.47e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	1.18e-05	5.47e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—EGFR—esophageal cancer	1.18e-05	5.46e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	1.18e-05	5.45e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PSME2—esophageal cancer	1.17e-05	5.43e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PSME1—esophageal cancer	1.17e-05	5.43e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—NOS3—esophageal cancer	1.17e-05	5.42e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—EP300—esophageal cancer	1.17e-05	5.41e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	1.16e-05	5.4e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	1.16e-05	5.37e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—CDKN1A—esophageal cancer	1.16e-05	5.36e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	1.15e-05	5.36e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—PIK3CA—esophageal cancer	1.15e-05	5.32e-05	CbGpPWpGaD
Risperidone—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	1.15e-05	5.31e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—CDKN1A—esophageal cancer	1.14e-05	5.29e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—PIK3CA—esophageal cancer	1.13e-05	5.23e-05	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—EP300—esophageal cancer	1.13e-05	5.23e-05	CbGpPWpGaD
Risperidone—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.13e-05	5.23e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—ERBB2—esophageal cancer	1.13e-05	5.22e-05	CbGpPWpGaD
Risperidone—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.12e-05	5.22e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—MYC—esophageal cancer	1.11e-05	5.16e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—ERBB2—esophageal cancer	1.11e-05	5.14e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—MYC—esophageal cancer	1.11e-05	5.13e-05	CbGpPWpGaD
Risperidone—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.1e-05	5.12e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—EP300—esophageal cancer	1.1e-05	5.1e-05	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—EP300—esophageal cancer	1.09e-05	5.08e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—NOS3—esophageal cancer	1.09e-05	5.07e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	1.09e-05	5.07e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—EGFR—esophageal cancer	1.09e-05	5.05e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—EP300—esophageal cancer	1.09e-05	5.04e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—MYC—esophageal cancer	1.08e-05	5.02e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—EGFR—esophageal cancer	1.08e-05	5.02e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—NOS3—esophageal cancer	1.07e-05	4.98e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	1.07e-05	4.98e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—NOS3—esophageal cancer	1.07e-05	4.97e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—NOS3—esophageal cancer	1.07e-05	4.97e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—PTGS2—esophageal cancer	1.07e-05	4.96e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—MYC—esophageal cancer	1.07e-05	4.94e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—CCND1—esophageal cancer	1.06e-05	4.94e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—EGFR—esophageal cancer	1.06e-05	4.91e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	1.05e-05	4.88e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—EGFR—esophageal cancer	1.04e-05	4.83e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	1.04e-05	4.83e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—CDKN1A—esophageal cancer	1.03e-05	4.78e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—CCND1—esophageal cancer	1.03e-05	4.77e-05	CbGpPWpGaD
Risperidone—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.03e-05	4.76e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	1.02e-05	4.75e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—CCND1—esophageal cancer	1.02e-05	4.74e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—ERBB2—esophageal cancer	1.02e-05	4.74e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	1.02e-05	4.74e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—MYC—esophageal cancer	1.02e-05	4.72e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.01e-05	4.69e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	1.01e-05	4.66e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—ERBB2—esophageal cancer	1e-05	4.65e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	1e-05	4.65e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—CCND1—esophageal cancer	9.95e-06	4.61e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—EGFR—esophageal cancer	9.94e-06	4.61e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	9.94e-06	4.61e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	9.89e-06	4.59e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	9.84e-06	4.57e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—EP300—esophageal cancer	9.8e-06	4.55e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—PTGS2—esophageal cancer	9.8e-06	4.55e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—CCND1—esophageal cancer	9.79e-06	4.54e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	9.78e-06	4.54e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—CDKN1A—esophageal cancer	9.62e-06	4.46e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—MYC—esophageal cancer	9.59e-06	4.45e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—CYP19A1—esophageal cancer	9.5e-06	4.41e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—CDKN1A—esophageal cancer	9.47e-06	4.39e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—EP300—esophageal cancer	9.46e-06	4.39e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—MYC—esophageal cancer	9.46e-06	4.39e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—PIK3CA—esophageal cancer	9.45e-06	4.38e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—EP300—esophageal cancer	9.41e-06	4.37e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—PIK3CA—esophageal cancer	9.38e-06	4.35e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—EGFR—esophageal cancer	9.38e-06	4.35e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	9.31e-06	4.32e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—EGFR—esophageal cancer	9.25e-06	4.29e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—PIK3CA—esophageal cancer	9.19e-06	4.26e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—EP300—esophageal cancer	9.16e-06	4.25e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	9.14e-06	4.24e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—TP53—esophageal cancer	9.14e-06	4.24e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—TP53—esophageal cancer	9.08e-06	4.21e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—PIK3CA—esophageal cancer	9.04e-06	4.19e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—CREBBP—esophageal cancer	9.03e-06	4.19e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CCND1—esophageal cancer	9.03e-06	4.19e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—EP300—esophageal cancer	9.01e-06	4.18e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—EP300—esophageal cancer	8.89e-06	4.13e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—TP53—esophageal cancer	8.89e-06	4.12e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CCND1—esophageal cancer	8.88e-06	4.12e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CCND1—esophageal cancer	8.86e-06	4.11e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—TP53—esophageal cancer	8.75e-06	4.06e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	8.73e-06	4.05e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	8.7e-06	4.03e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—HMOX1—esophageal cancer	8.67e-06	4.02e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—PIK3CA—esophageal cancer	8.63e-06	4e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	8.59e-06	3.99e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	8.57e-06	3.98e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—MYC—esophageal cancer	8.54e-06	3.96e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—CREBBP—esophageal cancer	8.51e-06	3.95e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	8.41e-06	3.9e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—EGFR—esophageal cancer	8.35e-06	3.88e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—TP53—esophageal cancer	8.35e-06	3.87e-05	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—PIK3CA—esophageal cancer	8.34e-06	3.87e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—ABCB1—esophageal cancer	8.32e-06	3.86e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—EP300—esophageal cancer	8.31e-06	3.85e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—MYC—esophageal cancer	8.24e-06	3.82e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—MYC—esophageal cancer	8.2e-06	3.81e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—EP300—esophageal cancer	8.17e-06	3.79e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—EP300—esophageal cancer	8.16e-06	3.78e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—EP300—esophageal cancer	8.15e-06	3.78e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—PIK3CA—esophageal cancer	8.14e-06	3.78e-05	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—PIK3CA—esophageal cancer	8.1e-06	3.76e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—NOS3—esophageal cancer	8.08e-06	3.75e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	8.08e-06	3.75e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—EGFR—esophageal cancer	8.06e-06	3.74e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—PIK3CA—esophageal cancer	8.03e-06	3.73e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—EGFR—esophageal cancer	8.02e-06	3.72e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—EP300—esophageal cancer	8e-06	3.71e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—MYC—esophageal cancer	7.98e-06	3.7e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—TP53—esophageal cancer	7.87e-06	3.65e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—MYC—esophageal cancer	7.85e-06	3.64e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	7.82e-06	3.63e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—EGFR—esophageal cancer	7.8e-06	3.62e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—TP53—esophageal cancer	7.77e-06	3.6e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—EGFR—esophageal cancer	7.68e-06	3.56e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—NOS3—esophageal cancer	7.62e-06	3.53e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—EP300—esophageal cancer	7.44e-06	3.45e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PTGS2—esophageal cancer	7.39e-06	3.43e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—PIK3CA—esophageal cancer	7.25e-06	3.36e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MYC—esophageal cancer	7.24e-06	3.36e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MYC—esophageal cancer	7.12e-06	3.3e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MYC—esophageal cancer	7.11e-06	3.3e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—EGFR—esophageal cancer	7.08e-06	3.28e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—TP53—esophageal cancer	7.01e-06	3.25e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	7e-06	3.25e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MYC—esophageal cancer	6.97e-06	3.24e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PTGS2—esophageal cancer	6.97e-06	3.23e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—EGFR—esophageal cancer	6.97e-06	3.23e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	6.96e-06	3.23e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—EGFR—esophageal cancer	6.95e-06	3.22e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	6.82e-06	3.16e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—PIK3CA—esophageal cancer	6.77e-06	3.14e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—TP53—esophageal cancer	6.77e-06	3.14e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—TP53—esophageal cancer	6.74e-06	3.12e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—PIK3CA—esophageal cancer	6.67e-06	3.09e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—PIK3CA—esophageal cancer	6.58e-06	3.05e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—TP53—esophageal cancer	6.55e-06	3.04e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MYC—esophageal cancer	6.48e-06	3.01e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—TP53—esophageal cancer	6.45e-06	2.99e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	6.34e-06	2.94e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—EP300—esophageal cancer	6.15e-06	2.85e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	6.15e-06	2.85e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	6.05e-06	2.81e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	6.03e-06	2.8e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—PIK3CA—esophageal cancer	6.03e-06	2.8e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—TP53—esophageal cancer	5.94e-06	2.76e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	5.92e-06	2.75e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—TP53—esophageal cancer	5.85e-06	2.71e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—TP53—esophageal cancer	5.84e-06	2.71e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—EP300—esophageal cancer	5.8e-06	2.69e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—TP53—esophageal cancer	5.73e-06	2.66e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—CREBBP—esophageal cancer	5.56e-06	2.58e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	5.5e-06	2.55e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—TP53—esophageal cancer	5.32e-06	2.47e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—NOS3—esophageal cancer	4.98e-06	2.31e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PTGS2—esophageal cancer	4.56e-06	2.11e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PIK3CA—esophageal cancer	4.55e-06	2.11e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PIK3CA—esophageal cancer	4.29e-06	1.99e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—EP300—esophageal cancer	3.79e-06	1.76e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.8e-06	1.3e-05	CbGpPWpGaD
